207 related articles for article (PubMed ID: 30219040)
1. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
Retèl VP; Steuten LMG; Geukes Foppen MH; Mewes JC; Lindenberg MA; Haanen JBAG; van Harten WH
BMC Cancer; 2018 Sep; 18(1):895. PubMed ID: 30219040
[TBL] [Abstract][Full Text] [Related]
2. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
Lindenberg M; Retèl V; Rohaan M; van den Berg J; Haanen J; van Harten W
BMC Cancer; 2020 Jul; 20(1):712. PubMed ID: 32736535
[TBL] [Abstract][Full Text] [Related]
3. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
4. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
[TBL] [Abstract][Full Text] [Related]
10. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.
Li M; Basu A; Bennette C; Veenstra D; Garrison LP
Value Health; 2019 Jul; 22(7):777-784. PubMed ID: 31277824
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
[TBL] [Abstract][Full Text] [Related]
12. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
[TBL] [Abstract][Full Text] [Related]
13. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Tarhini A; Benedict A; McDermott D; Rao S; Ambavane A; Gupte-Singh K; Sabater J; Ritchings C; Aponte-Ribero V; Regan MM; Atkins M
Immunotherapy; 2018 Oct; 10(14):1241-1252. PubMed ID: 30175642
[TBL] [Abstract][Full Text] [Related]
14. Accounting for Cured Patients in Cost-Effectiveness Analysis.
Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
Cartun Z; Kunz WG; Heinzerling L; Tomsitz D; Guertler A; Westphalen CB; Ricke J; Weir W; Unterrainer M; Mehrens D
JAMA Dermatol; 2022 Dec; 158(12):1387-1393. PubMed ID: 36260321
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.
Salans M; Courtney PT; Yip A; Murphy JD
Cancer Med; 2021 Oct; 10(19):6618-6626. PubMed ID: 34402192
[TBL] [Abstract][Full Text] [Related]
17. Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.
Lindenberg MA; Retèl VP; van den Berg JH; Geukes Foppen MH; Haanen JB; van Harten WH
J Immunother; 2018; 41(9):413-425. PubMed ID: 30300260
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
20. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]